Healthcare Companies Report Appointments, Phase 1 Studies, and Corporate Growth - Research Report on HCA, Isis Pharmaceuticals, Oxygen Biotherapeutics, Insmed, and Zalicus PR Newswire NEW YORK, December 3, 2013 NEW YORK, December 3, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting HCA Holdings, Inc. (NYSE: HCA), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Insmed Incorporated (NASDAQ: INSM), and Zalicus Inc. (NASDAQ: ZLCS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. HCA Holdings, Inc. Research Report On November 26, 2013, HCA Holdings, Inc. (HCA) announced the appointment of Gregory R. Angle as President of HCA's Salt Lake City-based Mountain Division, who will replace John Hanshaw, effective January 1, 2014. According to the Company, Angle will be responsible for 10 hospitals in Utah, Idaho, and Alaska. Chuck Hall, President of HCA's National Group, stated, "Greg is a healthcare industry veteran and a skilled hospital operator who has held several facility and multi-facility senior leadership roles throughout his 30-year career. He is a proven leader and innovator, and we are pleased to welcome him to the Mountain Division." The Full Research Report on HCA Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/be59_HCA Isis Pharmaceuticals, Inc. Research Report On November 26, 2013, Isis Pharmaceuticals, Inc. (Isis Pharmaceuticals) announced that it has initiated a Phase 1 study for ISIS-GSK3[Rx] and has earned a $3 million milestone payment from GlaxoSmithKline (GSK). According to the Company, it will develop ISIS-GSK3[Rx] to Phase 2 proof-of-concept, after which GSK has an exclusive option to in-license the program and further develop and commercialize the asset. B. Lynne Parshall, Chief Operating Officer of Isis Pharmaceuticals, stated, "We are very pleased to advance ISIS-GSK3[Rx] into a clinical study in a therapeutic area where there is a significant need for better therapies. The versatility and broad applicability of our technology enables us to discover and develop antisense drugs to a diverse range of targets. We look forward to evaluating this important new drug in this underserved disease space." The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/fcfc_ISIS Oxygen Biotherapeutics, Inc. Research Report On November 27, 2013, Oxygen Biotherapeutics, Inc.'s (Oxygen Biotherapeutics) stock jumped 20.59% and closed the day at $6.50 per share. Over the previous three day trading period, the Company's stock climbed 19.93%, compared to the Dow Jones Industrial Average which went up by 0.20% during the same period. The Full Research Report on Oxygen Biotherapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5700_OXBT Insmed Incorporated Research Report On November 27, 2013, Insmed Incorporated's (Insmed) stock was up by 6.28%, closing the day at $16.08 per share. The Company's stock went up by 5.10% during the past three trading days, compared to the Nasdaq composite which went up by 1.33% over the same period. The Full Research Report on Insmed Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9c5b_INSM Zalicus Inc. Research Report On November 27, 2013, Zalicus Inc.'s (Zalicus) stock reflected an increase of 7.83% as it closed the day at $1.24 per share. For the past three trading days, the Company's stock went up significantly by 34.78%, compared to the Dow Jones Industrial Average which went up by 0.20% during the same three trading day period. The Full Research Report on Zalicus Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/cbb5_ZLCS EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Healthcare Companies Report Appointments, Phase 1 Studies, and Corporate Growth - Research Report on HCA, Isis Pharmaceuticals,
Press spacebar to pause and continue. Press esc to stop.